Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Boosted by Tang Capital Management LLC

Tang Capital Management LLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 16.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,429,500 shares of the biotechnology company's stock after buying an additional 1,200,000 shares during the period. Aurinia Pharmaceuticals makes up approximately 5.0% of Tang Capital Management LLC's portfolio, making the stock its 2nd largest position. Tang Capital Management LLC owned about 5.89% of Aurinia Pharmaceuticals worth $75,697,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Kingswood Wealth Advisors LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $248,000. Union Bancaire Privee UBP SA purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at about $108,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock worth $273,000 after buying an additional 2,857 shares during the period. Blue Trust Inc. raised its holdings in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 6,174 shares in the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $135,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now owns 153,484 shares of the company's stock, valued at approximately $1,263,173.32. This represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph M. Miller sold 61,859 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares in the company, valued at $5,068,120. This represents a 8.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 343,898 shares of company stock worth $2,753,094. Company insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH traded down $0.14 during trading hours on Friday, hitting $8.13. The company had a trading volume of 1,194,834 shares, compared to its average volume of 1,326,821. The business has a 50 day moving average of $8.02 and a 200-day moving average of $8.27. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a 1-year low of $5.11 and a 1-year high of $10.67. The company has a market cap of $1.10 billion, a PE ratio of -54.16 and a beta of 1.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. The firm had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. As a group, equities research analysts expect that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.